National brain tumour research funding needs to increase to £35 million a year
3D biopsies, nano therapeutics and proprietary treatments
Researchers have obtained a highly accurate recreation of glioblastoma features using a novel 3D microscopy analysis providing new information to help with diagnosis, by finding therapeutical targets and designing immunotherapeutical strategies. This new analysis of 3D images and quantitative data will help to appreciate from within how the tumour is built in its full dimensionality, and to identify where different cell types are located. This approach showed the alterations in tumour blood vessels, and also showed that these vascular wall abnormalities do not hinder the entrance of lymphocytes T (which offer potential defence against tumoral cells), which is relevant for the design and use of immunotherapies targeting malignant cells.
As we all know gliomas can be hard to treat using current regimens that rely on surgery, radiation, chemotherapy and their combinations. Two of the major challenges in the treatment of gliomas include poor transport of chemotherapeutics across the blood brain barrier and undesired side effects of these therapeutics on healthy tissues. To get enough medicine across the blood brain barrier, a high dosage of medication is required, but that introduces more toxicity into the body and can cause problems. This article reports a new glioma-targeted nano-therapeutic that will only address tumour cells offering increased effectiveness and reduced side effects.
An industry update now on a series of discoveries and breakthroughs in oncology targeting Glioblastoma. Researchers in Canada, the USA, and Israel have announced breakthrough discoveries that could transform the field for years to come. This item looks at the pharma sectors own studies for proprietary treatments (basically treatments that they own). Projections for the Global Brain Tumour Therapeutics Market are expected to hit $3.4 billion by the end of 2025.
Further industry news as a patent application related to NanoZolid® for treatment of brain cancers has been filed to the European patent office. The patent application relates to treating brain cancer with intratumoral depots providing a controlled drug release at the tumour site.
Finally this week there is space to link to the Journal of Neuro-Oncology and an issue focused on immunotherapy for brain tumours as well as the most recent issue of the Journal of Neuro-Oncology which includes subjects such as;
- The use and efficacy of chemotherapy and radiotherapy in children and adults with pilocytic astrocytoma
- What effects does awake craniotomy have on functional and survival outcomes for glioblastoma patients?
If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.